20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) has presented additional analyses from SOLOIST and SCORED Phase 3 trials evaluating heart failure candidate sotagliflozin, a dual SGLT1 & SGLT2 inhibitor.
- Data were presented at the ESC Congress 2021 - The Digital Experience.
- In the SOLOIST trial, sotagliflozin was evaluated against the standard of care in 1,222 Type 2 diabetes patients who had been hospitalized with worsening heart failure.
- In the trial, the drug posted a 33% absolute risk reduction on an endpoint that combined cardiovascular death and hospitalizations or urgent office visits for heart failure.
- Investigators noticed the benefits within one month of treatment.
- Researchers tested the drug against the standard of care in certain patients with Type 2 diabetes, chronic kidney disease, and cardio risks in the SCORED trial. It enrolled 10,584 patients.
- Sotagliflozin posted a 26% risk reduction on the same composite endpoint, and investigators saw benefits within three months.
- Lexicon had previously released the SOLOIST and SCORED results, but new analyses from sotagliflozin's higher dose (400 mg) were associated with a more pronounced risk reduction and no new safety concerns.
- Price Action: LXRX shares are up 5.19% at $3.65 during the market session on the last check Monday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!